|Dr. Richard M. Toselli||Pres, CEO, Chief Medical Officer & Director||N/A||N/A||1958|
|Dr. Robert S. Langer Jr.||Co-Founder and Member of Scientific Advisory Board||N/A||N/A||1949|
|Dr. Joseph Philip Vacanti||Co-Founder||N/A||N/A||1949|
|Mr. Jeffrey Modestino||Principal Financial Officer, Principal Accounting Officer & Treasurer||N/A||N/A||N/A|
|Mr. William D'Agostino PE||Sr. VP of Operations||N/A||N/A||N/A|
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.
InVivo Therapeutics Holdings Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.